Brand Medications with Generic Alternatives Anticipated to be Approved in January

December 22, 2020 – Amitiza (lubiprostone) – for irritable bowel syndrome and opioid-induced constipation

Adverse reactions or quality problems experienced with the use of a recalled product can be reported to the FDA's MedWatch Adverse Event Reporting Program online, by mail, or by fax.

https://www.accessdata.fda.gov/scripts/medwatch/index.cfm

Download a form from https://www.fda.gov/safety/reporting-serious-problems-fda/forms- reporting-fda or call 1-800-332-1088 to request a reporting form. Then complete and return to the address on the form or submit by fax to 1-800-FDA-0178.